The Role of the Specialty Pharmacist in Optimizing Treatment for Amyotrophic Lateral Sclerosis: The Impact of Early Intervention, Patient-Centered Care, and Disease-Modifying ...
1.0 Credit / Neurology
View More
Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis
1.0 Credit / Immunology, Neurology
View More
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
1 Credit / Cardiology, Neurology
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmacist Credit)
2.0 Credits / Human Trafficking, Law
View More
From Treatment to Prevention: Navigating the Expanding Hereditary Angioedema Treatment Landscape
August 13, 2025 | 1:00 PM & 8:00 PM EDT
View More
Innovations in Hidradenitis Suppurativa Treatment: Navigating the Evolving Landscape for Managed Care Professionals
August 19, 2025 | 1:00 PM & 8:00 PM ET
View More
Optimizing Outcomes in Myasthenia Gravis: Therapeutic Advances and Value-Based Care Models
August 21, 2025 | 1:00 PM ET & 8:00 PM ET
View More
Managed Care Insights on the Advances in the Eosinophilic Esophagitis Treatment Landscape
1.0 Credit / Gastroenterology, Immunology, Rare Diseases
View More
Empagliflozin Reduces HF Risk After AMI in Patients With or Without Diabetes, CKD
October 30th 2025Though patients with type 2 diabetes or chronic kidney disease (CKD) face a greater risk of heart failure (HF) following acute myocardial infarction (AMI), patients without those comorbidities also benefit from empagliflozin.
Clinical and Patient Definitions of Acute COPD Exacerbation Recovery Differ
October 30th 2025Despite clinical definitions suggesting patients recover from exacerbations within 2 weeks of hospital discharge, most patients in a qualitative survey believed they had not achieved recovery within 3 months.